Aspirin Resistance in Coronary Artery Disease with Hypertensive Patients

Abstract

Aspirin is gold standard for antiplatelet therapy in cardiovascular treatment today. It exerts its antiplatelet effect by acetylation of the platelet cyclooxygenase, resulting in an irreversible inhibition of platelet- dependent thromboxane formation. However, aspirin has been shown to have variable antiplatelet activity in individual patients. Previous studies estimated that 5% to 45% of population do not achieve an adequate antiplatelet effect from aspirin. Studies about aspirin resistance have never been done in Indonesian hospitals. This study was initiated to investigate the prevalence of aspirin resistance and influencing factors of aspirin resistance in coronary artery disease with hypertensive patients by using an established method of optical platelet aggregation. Fourty three patients were involved in this study. The sampling of this cross sectional study was conducted at Dr. Soetomo Hospital Surabaya in June 2012. Of the patients studied, there were no aspirin resistant and only 2 (4.7%) were aspirin semiresponders. It can be concluded that coronary artery disease patients with hypertension to aspirin as antiplatelet agent were good. Similar research is needed to be conducted with more sample sizes in coronary artery disease patients with two or more comorbid. In addition, further research is needed to determine genotyping between good or poor patient’s respond to aspirin. Keywords: